Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Systemic Treatment in Patients with Hepatocellular Carcinoma and Advanced Liver Dysfunction

April 30, 2025

[Gut] Scientists discuss how the clinical course of cirrhosis can affect eligibility to treatment in the modern era of systemic therapy for HCC.

POU6F2 Promotes Liver Metastasis of Gastric Adenocarcinoma by Dual Mechanism of Transcriptional Upregulation of SNAI1 and IGF2/PI3K/AKT Signaling-Induced Conversion of Hepatic Stellate Cells into...

April 29, 2025

[British Journal of Cancer] POU6F2 expression was examined by real-time PCR, Western blot, and immunohistochemical staining.

Solute Carrier Family 2 Member 2 (Glucose Transporter 2): A Common Factor of Hepatocyte and Hepatocellular Carcinoma Differentiation

April 28, 2025

[PLOS One] Scientists investigated SLC2A2’s role in liver differentiation using in silico, in vitro, and in vivo approaches.

m6a-Modified MIR670HG Suppresses Tumor Liver Metastasis through Enhancing Kupffer Cell Phagocytosis

April 28, 2025

[Cellular and Molecular Life Sciences] Researchers demonstrated that the MIR670 host gene (MIR670HG) significantly suppressed tumor liver metastasis by enhancing phagocytosis of various tumor cells by Kupffer cells.

Ketogenesis Mitigates Metabolic Dysfunction-Associated Steatotic Liver Disease through Mechanisms That Extend beyond Fat Oxidation

April 28, 2025

[Journal of Clinical Investigation] Researchers performed stable-isotope tracing and formal flux modeling to quantify hepatic oxidative fluxes in humans across the spectrum of metabolic dysfunction-associated steatotic liver disease-metabolic dysfunction-associated steatohepatitis, and in mouse models of impaired ketogenesis.

Copper-Mediated SEC14L3 Promotes Cuproptosis to Inhibit Hepatocellular Carcinoma Growth via ERK/YY1/FDX1 Axis

April 25, 2025

[Communications Biology] Researchers revealed that SEC14L3 expression was downregulated in HCC cells and tissues and correlated with advanced stages and poor prognosis.

B Cell-Derived Acetylcholine Promotes Liver Regeneration by Regulating Kupffer Cell and Hepatic CD8+ T Cell Function

April 25, 2025

[Immunity] Scientists demonstrated that B cells expressing choline acetyltransferase, which synthesizes acetylcholine, were required for liver regeneration.

Gene-Based Therapies for Steatotic Liver Disease

April 25, 2025

[Molecular Therapy] While preclinical research continues to deepen our understanding of genetic factors, early-stage clinical trials involving gene-based steatotic liver disease therapies, including transient antisense and small molecule approaches, are helping prioritize therapeutic targets.

QPS Expands Offerings With Robust Pharmacology Disease Models, Including MASH, Ulcerative Colitis, Wound Healing, and Psoriasis

April 25, 2025

[QPS (BioSpace)] QPS is pleased to announce the expansion of its pharmacology disease models portfolio to include highly relevant models for metabolic dysfunction-associated steatohepatitis (MASH), ulcerative colitis, wound healing, and psoriasis.

TREMFYA® (Guselkumab) Receives European Commission Approval for Adults with Moderately to Severely Active Ulcerative Colitis, Strengthening Johnson & Johnson’s Leadership in Inflammatory Bowel Disease

April 25, 2025

[Johnson & Johnson] Johnson & Johnson announced that the European Commission has approved a Marketing Authorisation for TREMFYA^® for the treatment of adult patients with moderately to severely active ulcerative colitis who had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic treatment.

Hepatic MC3R Is a Regulator of Lipid Droplet Autophagy and Liver Steatosis

April 23, 2025

[Autophagy] Scientists reported that global mc3r knockout mice developed obesity with increased hepatic triglyceride accumulation and blunted hepatocellular autophagosome-lysosome docking, leading to defective lipid droplet clearance.

Increased Risk of Hepatocellular Carcinoma in HBeAg-Negative Indeterminate Phase Compared to HBeAg-Negative Chronic Infection

April 23, 2025

[Hepatology] In patients with indeterminate phase HBeAg-negative chronic hepatitis B, those with normal alanine aminotransferase (ALT) and high hepatitis B virus (HBV) DNA showed a higher HCC risk than those with abnormal ALT and low HBV DNA, with no difference between treated and untreated patients in either group.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!